The effects of anti-DNA topoisomerase II drugs, etoposide and ellipticine, are modified in root meristem cells of Allium cepa by MG132, an inhibitor of 26S proteasomes

Żabka, Aneta; Winnicki, Konrad; Polit, Justyna Teresa; Maszewski, Janusz

doi:10.1016/j.plaphy.2015.07.016

Cited by 7 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data have indicated that the formation of •NO/•NOderived species in cancer cells can induce a reduction in the level of TOPI via the ubiquitin/26S proteasome pathway [64]. Exploring combinatorial approaches by combining proteasome inhibitors such as MG132 and lactacystin along with topo-active drugs including SN-38 have been reported to potentiate anticancer effects in cancer cells [261,297,298].…”

Section: Emt and Topo-active Drugsmentioning

confidence: 99%

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review

Sharma,

Bahot,

Sekar

et al. 2024

Cancers

View full text Add to dashboard Cite

In recent years, the emergence of cancer drug resistance has been one of the crucial tumor hallmarks that are supported by the level of genetic heterogeneity and complexities at cellular levels. Oxidative stress, immune evasion, metabolic reprogramming, overexpression of ABC transporters, and stemness are among the several key contributing molecular and cellular response mechanisms. Topo-active drugs, e.g., doxorubicin and topotecan, are clinically active and are utilized extensively against a wide variety of human tumors and often result in the development of resistance and failure to therapy. Thus, there is an urgent need for an incremental and comprehensive understanding of mechanisms of cancer drug resistance specifically in the context of topo-active drugs. This review delves into the intricate mechanistic aspects of these intracellular and extracellular topo-active drug resistance mechanisms and explores the use of potential combinatorial approaches by utilizing various topo-active drugs and inhibitors of pathways involved in drug resistance. We believe that this review will help guide basic scientists, pre-clinicians, clinicians, and policymakers toward holistic and interdisciplinary strategies that transcend resistance, renewing optimism in the ongoing battle against cancer.

show abstract

Section: Emt and Topo-active Drugsmentioning

confidence: 99%

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review

Sharma,

Bahot,

Sekar

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Data have indicated that formation of •NO/•NO-derived species in cancer cells can induce the reduction in the level of Topo I via the ubiquitin/26S proteasome pathway [64]. Exploring combinatorial approaches by combining proteasome inhibitors such as MG132 and lactacystin along with Topo active drugs including SN-38 have been reported to potentiate anticancer effects in cancer cells [261], [297,298].…”

Section: -2 Emt and Topo-active Drugsmentioning

confidence: 99%

Cracking the Code: Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review

Sinha

2023

Preprint

View full text Add to dashboard Cite

In recent years, the emergence of cancer drug resistance is one of the crucial tumor hallmarks which is supported by the level of genetic heterogeneity and complexities at cellular levels. Oxidative stress, immune evasion, metabolic reprogramming, overexpression of ABC transporters and stemness are among the several key contributing molecular and cellular response mechanisms. Topo-active drugs, e.g., doxorubicin and topotecan, are clinically active and are utilized extensively against a wide variety of human tumors and often results in the development of resistance and failure to therapy. Thus, there is an urgent need for an incremental and comprehensive understanding of mechanisms of cancer drug resistance specifically in the context of topo-active drugs. This review delves into the intricate mechanistic aspects of these intracellular and extracellular topo-active drug resistance mechanisms and explores use of potential combinatorial approaches by utilizing various topo-active drugs and inhibitors of pathways involved in drug resistance. We believe that this review will help guide basic scientists, pre-clinicians, clinicians, and policymakers toward holistic and interdisciplinary strategies that transcend resistance, renewing optimism in the ongoing battle against cancer.

show abstract

Benzothienoquinazolinones as new multi-target scaffolds: Dual inhibition of human Topoisomerase I and tubulin polymerization

Ceramella

Caruso

Occhiuzzi

et al. 2019

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

The effects of anti-DNA topoisomerase II drugs, etoposide and ellipticine, are modified in root meristem cells of Allium cepa by MG132, an inhibitor of 26S proteasomes

Cited by 7 publications

References 62 publications

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review

Cracking the Code: Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review

Benzothienoquinazolinones as new multi-target scaffolds: Dual inhibition of human Topoisomerase I and tubulin polymerization

Contact Info

Product

Resources

About